Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed467%
terminated117%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
unknownphase_1

ImmunoBreast - A Phase Ib Study

NCT04609215
completedphase_2

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma

NCT02799238
completedphase_1

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients

NCT01984658
terminatedphase_2

Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan

NCT02060955
completedphase_1

Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

NCT01422850
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04609215Phase 1

ImmunoBreast - A Phase Ib Study

Unknown
NCT02799238Phase 2

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma

Completed
NCT01984658Phase 1

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients

Completed
NCT02060955Phase 2

Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan

Terminated
NCT01422850Phase 1

Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Completed
NCT00891345Phase 1

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6